07:34 AM EDT, 04/01/2025 (MT Newswires) -- Quantum BioPharma ( QNTM ) , on Tuesday said it has entered into a joint clinical study with Massachusetts General Hospital (MGH) scientists to validate a novel positron emission tomography (PET) imaging technique.

The PET technique will be assessed for its ability to monitor myelin integrity and demyelination in people with multiple sclerosis (MS). Quantum BioPharma ( QNTM ) is developing its lead compound, Lucid-MS, a new chemical entity shown to prevent and reverse myelin degradation in preclinical models.

"We are very excited about the potential of this novel PET biomarker to directly visualize and measure demyelination in the central nervous system", said Dr. Andrzej Chruscinski, vice-president, scientific and clinical affairs at Quantum Biopharma ( QNTM ). "We expect that this biomarker will be an important diagnostic tool in future MS trials investigating therapies that can prevent demyelination and promote remyelination. This is very relevant to our Lucid-MS clinical development program as Lucid-MS has been shown to protect the myelin sheath and prevent demyelination in animal models of MS."

The company's shares were last seen down US$0.07, to US$7.64, in New York trading.